EG546638 Activators
Ube2d4, known as ubiquitin-conjugating enzyme E2D 4, plays a crucial role in the regulation of protein ubiquitination. Predicted to enable ubiquitin conjugating enzyme activity, it is anticipated to act upstream of or within protein ubiquitination processes. The intricate network of chemical activators revealed in the table showcases diverse pathways and mechanisms influencing Ube2d4 activation. Pyrvinium Pamoate targets Wnt/β-catenin signaling, whereas Dorsomorphin modulates the AMPK/mTOR pathway, indirectly stimulating Ube2d4. Nordihydroguaiaretic Acid, through the Nrf2-Keap1 pathway, and SB202190, via p38 MAPK inhibition, also contribute to Ube2d4 activation by influencing associated cellular processes.
Ruxolitinib, BAY 11-7082, and Perifosine act as indirect activators through the JAK/STAT, NF-κB, and PI3K/Akt pathways, respectively. Furthermore, 6-Aminonicotinamide disrupts the NAD+/SIRT1/AMPK axis, and TAK-242 influences the TLR4/NF-κB pathway, both indirectly enhancing Ube2d4 activity. Brefeldin A, by disturbing ER-to-Golgi transport, alters the ER stress and UPR pathways, contributing to Ube2d4 activation. Finally, AZD5363 modulates the PI3K/AKT/mTOR signaling cascade, indirectly activating Ube2d4. This diverse array of chemical modulators offers insights into potential strategies for manipulating Ube2d4 function within specific cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pyrvinium Pamoate | 3546-41-6 | sc-476920A sc-476920 | 250 mg 500 mg | $228.00 $422.00 | ||
Pyrvinium Pamoate, a FDA-approved anthelmintic drug, is known to enhance Ube2d4 activity. It targets the Wnt/β-catenin signaling pathway by inhibiting CK1α, leading to increased ubiquitin conjugating enzyme activity. This, in turn, up-regulates Ube2d4 expression, contributing to enhanced protein ubiquitination. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, a selective AMP-activated protein kinase (AMPK) inhibitor, indirectly stimulates Ube2d4. By inhibiting AMPK, it alters cellular energy status, influencing the AMPK/mTOR pathway. This modulation indirectly activates Ube2d4, as the protein plays a role upstream of protein ubiquitination within this pathway. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
Nordihydroguaiaretic Acid acts as an indirect activator of Ube2d4. It influences the Nrf2-Keap1 antioxidant pathway by inhibiting Keap1, leading to Nrf2 stabilization. This subsequently triggers Ube2d4 activation, as it is predicted to act upstream of protein ubiquitination. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190, a p38 MAPK inhibitor, acts as an indirect activator of Ube2d4. By inhibiting p38 MAPK, it influences the MAPK signaling pathway, leading to altered Ube2d4 expression. This modulation indirectly up-regulates Ube2d4 activity, contributing to enhanced protein ubiquitination. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, indirectly activates Ube2d4. By inhibiting JAK signaling, it modulates the JAK/STAT pathway, influencing Ube2d4 expression and subsequently promoting protein ubiquitination. This indirect activation is a result of its impact on the signaling cascade associated with Ube2d4 function. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, acts as an indirect activator of Ube2d4. By inhibiting NF-κB, it influences the NF-κB signaling pathway, leading to altered Ube2d4 expression and enhanced protein ubiquitination. This modulation indirectly triggers Ube2d4 activity, contributing to its activation through the NF-κB signaling cascade. | ||||||
6-Aminonicotinamide | 329-89-5 | sc-278446 sc-278446A | 1 g 5 g | $156.00 $398.00 | 3 | |
6-Aminonicotinamide, an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), indirectly activates Ube2d4. By inhibiting NAMPT, it disrupts NAD+ synthesis, influencing the SIRT1/AMPK pathway. This modulation indirectly up-regulates Ube2d4 activity, contributing to enhanced protein ubiquitination through alterations in the NAD+/SIRT1/AMPK axis. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine, an Akt inhibitor, acts as an indirect activator of Ube2d4. By inhibiting Akt signaling, it influences the PI3K/Akt pathway, leading to altered Ube2d4 expression and enhanced protein ubiquitination. This modulation indirectly triggers Ube2d4 activity, contributing to its activation through the PI3K/Akt signaling cascade. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A, an ER-to-Golgi transport inhibitor, indirectly activates Ube2d4. By disrupting vesicular trafficking, it influences the ER stress response and the unfolded protein response (UPR). This modulation indirectly up-regulates Ube2d4 activity, contributing to enhanced protein ubiquitination through alterations in the ER stress and UPR pathways. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an AKT kinase inhibitor, acts as an indirect activator of Ube2d4. By inhibiting AKT, it influences the PI3K/AKT/mTOR pathway, leading to altered Ube2d4 expression and enhanced protein ubiquitination. This modulation indirectly triggers Ube2d4 activity, contributing to its activation through the PI3K/AKT/mTOR signaling cascade. | ||||||